Navigation Links
Nautilus Neurosciences Announces New Patent Issued
Date:2/1/2012

BEDMINSTER, N.J., Feb. 1, 2012 /PRNewswire/ -- Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company headquartered in Bedminster, New Jersey, announced today that United States Patent and Trademark Office has issued U.S. Patent 8,097,651 entitled "Diclofenac formulations and methods of use." This patent relates to methods and formulations for treating migraine. Additionally, methods are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting. The patent provides additional protection for Cambia™, Nautilus' marketed product for the treatment of migraine through June 2026. This patent was licensed to Nautilus for Cambia™ in the North American markets by the Swiss company APR Applied Pharma Research, and is now listed in the FDA's Orange Book.

This coverage is in addition to that provided by U.S. Patent Nos. 7,759,394; 7,482,377; and 6,974,595.

About CAMBIA™

Nautilus' lead product, CAMBIA™, is a novel treatment for acute migraine in adults. CAMBIA is the only prescription non-steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine. Engineered using Dynamic Buffering Technology (DBT), CAMBIA is specifically designed for fast, effective relief from the symptoms of migraine. Designed to treat the underlying pathophysiology of migraine, Cambia reaches peak blood levels within 15 minutes and has been proven to provide equally as rapid relief in migraine. The FDA approval of CAMBIA was based on two Phase 3 placebo-controlled trials showing that CAMBIA was superior to placebo in all four FDA-mandated co-primary end points for migraine -- pain, nausea, photophobia and phonophobia. Both studies also showed that reduction in pain intensity was significantly greater in the CAMBIA group than in the placebo group as early as 15 minutes following treatment, and headache response rates were superior to placebo for up to 24 hours.

Nautilus Neurosciences, Inc.

Nautilus Neurosciences is a neurology-focused specialty pharmaceutical company committed to providing the health care community with medically relevant products and services that directly benefit those affected by neurologic disorders. Nautilus is sponsored by Tailwind Capital and Galen Partners.

CONTACT: 
William Maichle
Chief Executive Officer
Nautilus Neurosciences, Inc.
908-393-7800
WMaichle@nautilusneurosciences.com

 

 


'/>"/>
SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
2. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
3. Intellect Neurosciences, Inc. to Present at BIO Asia International Conference
4. Intellect Neurosciences Files Appeal in Europe in Response to Opposition Proceedings Instituted by Elan Pharmaceuticals and Wyeth/Pfizer
5. Intellect Neurosciences, Inc. to Present at OneMedForum
6. Intellect Neurosciences Obtains Two New Patents in Japan for Its Alzheimers Immunotherapy Programs
7. Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimers Patent Application
8. Intellect Neurosciences Announces Its New CONJUMAB-A Platform Technology for Novel Treatments of Alzheimers Disease and Other Proteinopathies
9. Intellect Neurosciences Issues Letter to Shareholders
10. Intellect Neurosciences CEO to be Featured on Wall Street Reporter
11. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
(Date:4/18/2017)... Viverae ® , a leader in workplace ... IBM ® Watson Campaign Automation, implementing behavioral messaging ... a personalized experience. Through digital engagement, the platform prompts ... real time. The enhanced experience drives engagement by focusing ... they are in their journey to health. ...
(Date:4/18/2017)... 18, 2017  Socionext Inc. and SOINN Inc. ... 2016, in which Socionext extracts and delivers biometrics ... achieved initial results in reading ultrasound images from ... SOINN. The results will be introduced at Medtec ... at booths 4505 & 4507. In ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley Bobrow will be ... to publish in summer 2017. , Dr. Bobrow, MD, FACEP, FAHA, is an ... Medicine. He also serves as Medical Director for the Bureau of Emergency Medical Services ...
(Date:4/24/2017)... ... ... Emmanuel College is introducing enhancements to its RN-to-BSN Degree Program ... of 2017, Emmanuel’s program will allow registered nurses (RN)s to earn a Bachelor of ... little as $14,528. These changes will enable nurses to complete their degree in a ...
(Date:4/24/2017)... ... 2017 , ... Ridgecrest Herbals makes it a point to lead the Utah ... and support renewable energy. They believe this is a crucial part of their mission ... health issues, and maintain that destroying the environment in the pursuit of profit is ...
(Date:4/24/2017)... ... 2017 , ... Today, Bright Pink , a national non-profit organization focusing on the prevention ... , Bright Pink is proud to announce Katie Thiede as their new Chief Executive ... role as Chairman of the Board and launched a national search to find a ...
(Date:4/24/2017)... ... April 24, 2017 , ... The John P. McGovern Museum ... allows anyone, anywhere to track their cognitive health, and share results with their physicians. ... brain health on the museum's website. , BrainCheck founder, Dr. David Eagleman, formerly at ...
Breaking Medicine News(10 mins):